MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
AORT stock logo

AORT

Artivion, Inc.

$34.21
0.05
 (0.15%)
Delayed data
Exchange:  NYSE
Market Cap:  1.638B
Shares Outstanding:  8.75M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  James Patrick Mackin
Full Time Employees:  1600
Address: 
1655 Roberts Boulevard N.W.
Kennesaw
GA
30144
US
Website:  https://artivion.com
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/05 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue354,004388,537441,330
Gross Profit229,176248,781270,452
EBITDA26,78950,96849,203
Operating Income5,74238,87426,745
Net Income-30,690-13,3599,768

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets792,397789,101884,796
Total Liabilities510,617512,901436,564
Total Stockholders Equity281,780276,200448,232
Total Debt358,341362,258292,041
Cash and Cash Equivalents58,94053,46364,908

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow18,82522,23638,130
Capital Expenditure-7,430-11,188-39,041
Free Cash Flow11,39511,048-911
Net Income-30,690-13,3599,768
Net Change in Cash19,589-5,47711,445

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)778,120.186Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)791,963.649Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)787,300Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)75,837.837Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)77,187.061Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)76,732.528Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)79,889.128Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)81,743.538Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)81,118.641Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)410,428.387Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)417,730.279Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)415,270.384Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.720Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.730Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.690Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
388.537M  ?P/S
 (TTM)
: 
4.14
?Net Income
 (TTM)
: 
-13335000  ?P/E
 (TTM)
: 
183.66
?Enterprise Value
 (TTM)
: 
2.056B  ?EV/FCF
 (TTM)
: 
-2257.3
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
0.02  ?ROIC
 (TTM)
: 
0.03
?Net Debt
 (TTM)
: 
308.795M  ?Debt/Equity
 (TTM)
: 
0.65
?P/B
 (TTM)
: 
4  ?Current Ratio
 (TTM)
: 
2.99

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
95.03Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates AORT intrinsic value between $3.71 – $3.90 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate AORT Intrinsic Value

Common questions about AORT valuation

Is Artivion, Inc. (AORT) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Artivion, Inc. (AORT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is AORT a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AORT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is AORT’s P/E ratio?

You can see AORT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for AORT?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is AORT a good long-term investment?

Whether AORT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

AORT

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.15
MARKETSnap

Trading Metrics:

Open: 33.6   Previous Close: 34.16
Day Low: 32.84   Day High: 34.66
Year Low: 21.97   Year High: 48.25
Price Avg 50: 38.27   Price Avg 200: 40.03
Volume: 358396   Average Volume: 444669

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
23-04-2026 16:15
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
08-04-2026 04:47
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
03-03-2026 16:10
Artivion to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Artivion Continues Building Toward Bigger And Better Things
29-12-2025 14:04
Artivion Continues Building Toward Bigger And Better Things
Artivion, Inc. (NYSE:AORT) Given Consensus Rating of “Moderate Buy” by Analysts
18-12-2025 01:58
Artivion, Inc. (NYSE:AORT) Given Consensus Rating of “Moderate Buy” by Analysts

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read